Dahm Johannes B, Willems Tine, Wolpers Hans Georg, Nordbeck Hans, Becker Jürgen, Ruppert Jörg
Department of Cardiology & Angiology, Heart-& Vascular Center Neu-Bethlehem, Göttingen, Germany.
EuroIntervention. 2009 Jan;4(4):502-8. doi: 10.4244/eijv4i4a85.
Recurrent stenosis and stent thrombosis are still major concerns after drug eluting stent placement which inhibits not only the restenostic process but endothelialisation as well. In contrast, through accelerating rapid endothelialisation and development of an earlier functional endothelial layer, passive coatings have shown encouraging results. The objective of the present study was to investigate the clinical outcome and rate of recurrent stenosis of silicon carbide passive coated cobalt chromium stents (PROKinetic Coronary Stent with PROBIO coating, Biotronik AG, Switzerland) on restenosis after percutaneous coronary intervention.
Percutaneous coronary stent deployment was carried out in 161 lesions in 145 consecutive patients. The primary combined endpoint was the rate of target-lesion revascularisation (TLR) and late lumen loss; the secondary endpoints were the procedural success and the major adverse cardiac events at 6-months follow-up. Out of 145 patients, 141 were successfully amenable to a silicon carbide coated stent (PRO-Kinetic, Biotronik AG, Switzerland) implantation (97.2% procedural success). At follow-up, the late loss was 0.75 +/- 0.71 mm. (in-stent) respectively 0.79 +/- 0.72 mm (in-segment), TLR was 4.9% and MACE was 5.6%.
By augmenting rapid endothelialisation and development of an earlier functional endothelial layer, silicon carbide (PROBIO) as a passive coating on cobalt chromium stents has shown encouraging results relative to success rates, clinical outcome, TLR and late-loss in a cohort of patients with extended coronary artery disease.
药物洗脱支架置入术后,再狭窄和支架内血栓形成仍是主要问题,因为药物洗脱支架不仅抑制再狭窄过程,还抑制内皮化。相比之下,通过加速快速内皮化和更早形成功能性内皮层,被动涂层已显示出令人鼓舞的结果。本研究的目的是调查碳化硅被动涂层钴铬支架(带有PROBIO涂层的PROKinetic冠状动脉支架,百多力公司,瑞士)在经皮冠状动脉介入治疗后再狭窄方面的临床结果和再狭窄率。
对145例连续患者的161处病变进行了经皮冠状动脉支架置入术。主要联合终点是靶病变血运重建率(TLR)和晚期管腔丢失;次要终点是手术成功率和6个月随访时的主要不良心脏事件。145例患者中,141例成功接受了碳化硅涂层支架(PRO-Kinetic,百多力公司,瑞士)植入(手术成功率97.2%)。随访时,晚期丢失分别为0.75±0.71mm(支架内)和0.79±0.72mm(节段内),TLR为4.9%,MACE为5.6%。
在一组患有广泛性冠状动脉疾病的患者中,作为钴铬支架上的被动涂层,碳化硅(PROBIO)通过增强快速内皮化和更早形成功能性内皮层,在成功率、临床结果、TLR和晚期丢失方面已显示出令人鼓舞的结果。